cis-Platinum combination chemotherapy of bladder cancer. An update

S. D. Williams, Lawrence Einhorn, J. P. Donohue

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The combination of cis-platinum (DDP), adriamycin, and 5-fluorouracil was evaluated in 44 patients with advanced urothelial cancer, 39 of whom were evaluable for response. There were 18 partial remissions (46.2%) and no complete responses. Remissions were clinically meaningful, but of short duration. Four patients had bulky pelvic disease that was made respectable by chemotherapy, but none of these patients remained disease-free. These results are not superior to that expected from DDP as a single agent. In addition, there appears to be little or no survival benefit associated with chemotherapy. DDP represents an advance in the treatment of bladder cancer, but additional active agents and innovative approaches are needed.

Original languageEnglish
Pages (from-to)335-338
Number of pages4
JournalCancer Clinical Trials
Volume2
Issue number4
StatePublished - 1979

Fingerprint

Combination Drug Therapy
Urinary Bladder Neoplasms
Cisplatin
Drug Therapy
Fluorouracil
Doxorubicin
Survival
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

cis-Platinum combination chemotherapy of bladder cancer. An update. / Williams, S. D.; Einhorn, Lawrence; Donohue, J. P.

In: Cancer Clinical Trials, Vol. 2, No. 4, 1979, p. 335-338.

Research output: Contribution to journalArticle

Williams, S. D. ; Einhorn, Lawrence ; Donohue, J. P. / cis-Platinum combination chemotherapy of bladder cancer. An update. In: Cancer Clinical Trials. 1979 ; Vol. 2, No. 4. pp. 335-338.
@article{f9113080515744c9a3b2767acb5f1ea1,
title = "cis-Platinum combination chemotherapy of bladder cancer. An update",
abstract = "The combination of cis-platinum (DDP), adriamycin, and 5-fluorouracil was evaluated in 44 patients with advanced urothelial cancer, 39 of whom were evaluable for response. There were 18 partial remissions (46.2{\%}) and no complete responses. Remissions were clinically meaningful, but of short duration. Four patients had bulky pelvic disease that was made respectable by chemotherapy, but none of these patients remained disease-free. These results are not superior to that expected from DDP as a single agent. In addition, there appears to be little or no survival benefit associated with chemotherapy. DDP represents an advance in the treatment of bladder cancer, but additional active agents and innovative approaches are needed.",
author = "Williams, {S. D.} and Lawrence Einhorn and Donohue, {J. P.}",
year = "1979",
language = "English",
volume = "2",
pages = "335--338",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - cis-Platinum combination chemotherapy of bladder cancer. An update

AU - Williams, S. D.

AU - Einhorn, Lawrence

AU - Donohue, J. P.

PY - 1979

Y1 - 1979

N2 - The combination of cis-platinum (DDP), adriamycin, and 5-fluorouracil was evaluated in 44 patients with advanced urothelial cancer, 39 of whom were evaluable for response. There were 18 partial remissions (46.2%) and no complete responses. Remissions were clinically meaningful, but of short duration. Four patients had bulky pelvic disease that was made respectable by chemotherapy, but none of these patients remained disease-free. These results are not superior to that expected from DDP as a single agent. In addition, there appears to be little or no survival benefit associated with chemotherapy. DDP represents an advance in the treatment of bladder cancer, but additional active agents and innovative approaches are needed.

AB - The combination of cis-platinum (DDP), adriamycin, and 5-fluorouracil was evaluated in 44 patients with advanced urothelial cancer, 39 of whom were evaluable for response. There were 18 partial remissions (46.2%) and no complete responses. Remissions were clinically meaningful, but of short duration. Four patients had bulky pelvic disease that was made respectable by chemotherapy, but none of these patients remained disease-free. These results are not superior to that expected from DDP as a single agent. In addition, there appears to be little or no survival benefit associated with chemotherapy. DDP represents an advance in the treatment of bladder cancer, but additional active agents and innovative approaches are needed.

UR - http://www.scopus.com/inward/record.url?scp=0018740905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018740905&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 335

EP - 338

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 4

ER -